Literature DB >> 12511434

Contraindications to the use of metformin.

G C Jones, J P Macklin, W D Alexander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12511434      PMCID： PMC1124930          DOI： 10.1136/bmj.326.7379.4

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

Authors:  K Cusi; A Consoli; R A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

Review 2.  Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'.

Authors:  J D Lalau; J M Race
Journal:  Diabetes Obes Metab       Date:  2001-06       Impact factor: 6.577

3.  Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.

Authors:  A M Emslie-Smith; D I Boyle; J M Evans; F Sullivan; A D Morris
Journal:  Diabet Med       Date:  2001-06       Impact factor: 4.359

Review 4.  Clinical pharmacokinetics of metformin.

Authors:  A J Scheen
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

5.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.

Authors:  K Malmberg
Journal:  BMJ       Date:  1997-05-24

6.  Contraindications to metformin therapy in patients with NIDDM.

Authors:  T V Sulkin; D Bosman; A J Krentz
Journal:  Diabetes Care       Date:  1997-06       Impact factor: 19.112

7.  Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis.

Authors:  J D Lalau; C Lacroix; B De Cagny; A Fournier
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

Review 8.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  S Salpeter; E Greyber; G Pasternak; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Lactic acidosis rates in type 2 diabetes.

Authors:  J B Brown; K Pedula; J Barzilay; M K Herson; P Latare
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112
View more
  27 in total

1.  Contraindications to use of metformin. Age and creatinine clearance need to be taken into consideration.

Authors:  Andrew T Elder
Journal:  BMJ       Date:  2003-04-05

2.  Case report: adverse drug reactions in unrecognized kidney failure.

Authors:  Barbara Farrell; Kevin Pottie; William Hogg
Journal:  Can Fam Physician       Date:  2004-10       Impact factor: 3.275

Review 3.  Metformin's contraindications should be contraindicated.

Authors:  James McCormack; Kevin Johns; Hugh Tildesley
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

4.  Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.

Authors:  Savas Sipahi; Yalcin Solak; Seyyid Bilal Acikgoz; Ahmed Bilal Genc; Mehmet Yildirim; Ulku Yilmaz; Ahmet Nalbant; Ali Tamer
Journal:  Int Urol Nephrol       Date:  2016-04-21       Impact factor: 2.370

5.  Complications and characteristics of patients referred to a joint diabetes renal clinic in Ireland.

Authors:  H Thabit; B Besharatian; P J Conlon; D Smith
Journal:  Ir J Med Sci       Date:  2012-03-31       Impact factor: 1.568

Review 6.  Lactic acidosis induced by metformin: incidence, management and prevention.

Authors:  Jean-Daniel Lalau
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.606

7.  Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.

Authors:  Justin W Timbie; Rodney A Hayward; Sandeep Vijan
Journal:  Health Serv Res       Date:  2010-01-08       Impact factor: 3.402

Review 8.  Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.

Authors:  P Spallarossa; A Barsotti; R Cordera; G Ghigliotti; D Maggi; C Brunelli
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 9.  Individualising therapy for older adults with diabetes mellitus.

Authors:  Danelle Cayea; Cynthia Boyd; Samuel C Durso
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Metformin: effective and safe in renal disease?

Authors:  William Guy Herrington; Jeremy B Levy
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.